Shenzhen biotech that discovers original small-molecule drugs, known for its HDAC-inhibitor lymphoma drug chidamide.
Shenzhen biotech that discovers original small-molecule drugs, known for its HDAC-inhibitor lymphoma drug chidamide.
Sells its own patented drugs mainly to hospitals, so a drug's place on China's national reimbursement list is what turns approval into volume. Its lymphoma drug has also been licensed to partners for markets outside China.
In one line: A small, China-only Incyte.
Moat: narrow (IP / patents). Patent-protected first-in-class molecules discovered in-house rather than licensed-in generics.
Headquarters: Shenzhen, China · Founded: 2001 · Employees: 1,002
Size Shenzhen Chipscreen Biosciences (688321.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.18B, the 1864th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥18.74 on 18 Nov 2026.
Performance Over six months the shares fell 38.0%, against -17.3% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 26.8% over the last twelve months (peer median -1.5%); the operating margin is 11.7% (peer median -13.3%).
Valuation It trades at 60.4× forward earnings against a peer median of 18.6× (2nd most expensive of 10).
Capital Return on invested capital runs 4.6 points below its cost of capital (9.5% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.08B | CN¥908M | CN¥656M | CN¥516M | CN¥528M |
| Revenue growth | — | +38% | +27% | -2% | — |
| Gross profit | CN¥969M | CN¥765M | CN¥544M | CN¥434M | CN¥475M |
| EBITDA | n/a | CN¥155M | CN¥899,100 | -CN¥138M | CN¥48.3M |
| Net income | CN¥71.4M | CN¥51.0M | -CN¥115M | CN¥88.8M | CN¥17.5M |
| Free cash flow | -CN¥134M | -CN¥62.8M | -CN¥179M | -CN¥372M | -CN¥351M |
| Capital expenditure | CN¥321M | CN¥179M | CN¥268M | CN¥229M | CN¥400M |
| Total debt | CN¥1.46B | CN¥1.67B | CN¥1.46B | CN¥1.20B | CN¥1.05B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shenzhen Chipscreen Biosciences 688321.SS | $1.18B | -38% | +27% | 12% | 60.4× | n/a |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $45.7B | -13% | +6% | 27% | 33.4× | 13.4% |
| BeOne Medicines 688235.SS | $45.5B | +9% | +25% | 18% | 59.7× | 19.1% |
| HUTCHMED (China) 0013.HK | $2.38B | +14% | -9% | -6% | 35.9× | 47.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688321.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.3% | -4.9% | 4th lowest of 21 |
| 6-month return | -38.0% | -17.3% | 5th lowest of 21 |
| Distance from 52-week high | -48.6% | -39.3% | 8th lowest of 21 |
| Revenue growth (TTM) | +26.8% | -1.5% | 5th highest of 18 |
| Operating margin | 11.7% | -13.3% | 4th highest of 18 |
| Forward P/E | 60.4× | 18.6× | 2nd most expensive of 10 |
| ROIC minus cost of capital | -4.6 pp | -8.6 pp | 8th highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.18B | -38% | +27% | 12% | 60.4× | n/a | n/a |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.18B | -22% | +256% | -27% | n/a | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.18B | -50% | -17% | -304% | n/a | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.18B | -34% | +70% | -220% | n/a | n/a | n/a |
| Mabwell (Shanghai) Bioscience 688062.SS | China | $1.20B | -46% | +15% | -129% | n/a | n/a | n/a |
| Jiuzhitang 000989.SZ | China | $1.16B | -7% | +46% | 19% | 22.1× | -4.0% | -9.0% |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.21B | +26% | -6% | -19% | n/a | 44.1% | -13.2% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.21B | -22% | +117% | -89% | n/a | n/a | n/a |
| Harrow HROW | United States | $1.21B | +4% | +21% | 1% | 26.8× | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.22B | -49% | -77% | -2,324% | n/a | n/a | n/a |
| Idorsia IDIA.SW | Switzerland | $1.22B | -9% | -5% | -70% | n/a | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.23B | -10% | -29% | 3% | 21.3× | 7.0% | -5.3% |
| Kissei Pharmaceutical 4547.T | Japan | $1.14B | +3% | +6% | 6% | 14.5× | n/a | n/a |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.14B | -12% | -2% | 15% | 18.4× | 3.4% | -1.2% |
| Avalyn Pharma AVLN | United States | $1.23B | -1% | n/a | n/a | n/a | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| Cosmo CMHC.SW | Switzerland | $1.13B | -30% | -45% | -13% | 418.7× | n/a | n/a |
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 18.6× | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.25B | -16% | +14% | 19% | 11.9× | 3.4% | +27.9% |
| GC Biopharma 006280.KS | South Korea | $1.12B | -10% | -3% | 4% | 4.6× | n/a | n/a |
| GH Research GHRS | United States | $1.25B | -19% | n/a | n/a | n/a | n/a | n/a |